<DOC>
	<DOC>NCT02465515</DOC>
	<brief_summary>Albiglutide is an analogue of glucagon-like peptide-1 (GLP-1), used to treat type 2 diabetes This study will test whether albiglutide affects the occurrence of major cardiovascular events such as heart attacks or strokes and other important medical outcomes in persons with type 2 diabetes, when used alone or added to other diabetes treatments.</brief_summary>
	<brief_title>Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Men or women at least 40 years old. Women must be postmenopausal or using a highly effective method for avoidance of pregnancy. Diagnosis of type 2 diabetes. Established cardiovascular disease with at least one of the following: coronary artery disease, cerebrovascular disease, or peripheral arterial disease. HbA1c &gt;7.0% (53 mmol/mol) (based on the most recent documented laboratory measurement within 6 months). Able and willing to provide informed consent. Severely reduced kidney function: eGFR &lt;30 ml/min/1.73 m^2 (based on the last measured and documented laboratory measurement within 6 months) or renal replacement therapy. Use of a GLP1 receptor agonist at Screening. Severe gastroparesis History of pancreatitis or considered clinically at significant risk of developing pancreatitis during the course of the study. Personal or family history of medullary carcinoma of the thyroid or subject with multiple endocrine neoplasia type 2 (MEN2). Personal history of pancreatic neuroendocrine tumours. Medical history which might limit the subject's ability to take trial treatments for the duration of the study or to otherwise complete the study. Breastfeeding, pregnancy, or planning a pregnancy during the course of the study. Note: a pregnancy test will be performed on all women of child bearing potential prior to study entry. Known allergy to any GLP1 receptor agonist or excipients of albiglutide. Use of another investigational product within 30 days or according to local regulations, or currently enrolled in a study of an investigational device. Any other reason the investigator deems the subject to be unsuitable for the study.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>cardiovascular events /outcomes</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>albiglutide</keyword>
	<keyword>glucagon-like peptide-1 receptor agonist</keyword>
</DOC>